Cooper Companies (NASDAQ:COO) Director Buys $149,963.04 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Cynthia Lucchese purchased 1,784 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was acquired at an average cost of $84.06 per share, with a total value of $149,963.04. Following the transaction, the director directly owned 9,445 shares of the company’s stock, valued at approximately $793,946.70. This represents a 23.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Cooper Companies Price Performance

Cooper Companies stock traded down $0.96 during mid-day trading on Tuesday, hitting $82.88. 1,534,311 shares of the company were exchanged, compared to its average volume of 2,472,692. The company has a market capitalization of $16.24 billion, a PE ratio of 44.09, a price-to-earnings-growth ratio of 2.36 and a beta of 1.05. The business has a fifty day moving average of $74.99 and a 200 day moving average of $72.15. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $100.24. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period last year, the firm posted $1.04 EPS. The business’s revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies declared that its board has authorized a stock repurchase program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. increased its holdings in shares of Cooper Companies by 0.9% in the first quarter. American Century Companies Inc. now owns 45,616 shares of the medical device company’s stock valued at $3,848,000 after purchasing an additional 406 shares during the last quarter. Norinchukin Bank The grew its stake in Cooper Companies by 15.2% in the 1st quarter. Norinchukin Bank The now owns 10,294 shares of the medical device company’s stock valued at $868,000 after buying an additional 1,359 shares during the last quarter. Synovus Financial Corp grew its stake in Cooper Companies by 30.0% in the 1st quarter. Synovus Financial Corp now owns 41,684 shares of the medical device company’s stock valued at $3,516,000 after buying an additional 9,609 shares during the last quarter. FORA Capital LLC acquired a new stake in Cooper Companies during the first quarter worth approximately $984,000. Finally, Findlay Park Partners LLP acquired a new stake in Cooper Companies during the first quarter worth approximately $37,134,000. 24.39% of the stock is currently owned by institutional investors.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Board refresh and cooperation with an investor: CooperCompanies appointed Walter M. Rosebrough Jr. to the Board effective Jan. 3, 2026 and entered a cooperation agreement with activist/long-term investor Browning West. The move commits the company to consider additional board refreshment (including a medical‑tech director) and may reduce governance uncertainty while aligning a large investor with management. That can support confidence in strategic changes and long‑term value creation. CooperCompanies Appoints Walter M Rosebrough, Jr to its Board of Directors
• Positive Sentiment: Insider buying: Director Cynthia L. Lucchese bought 1,784 shares at an average $84.06 on Dec. 22, increasing her stake ~23%. Insider purchases are typically viewed positively by investors as a signal of confidence in the company’s outlook. SEC Filing: Director Purchase
• Neutral Sentiment: Third‑party coverage and context: Market summaries (Quiver/other outlets) highlight the board appointment, cooperation agreement, and broader insider buying activity; they also note mixed analyst views and recent revenue trends. This corroborates the items above but doesn’t add materially new catalysts beyond confirming investor and media attention. QuiverQuant: CooperCompanies Appoints Walt Rosebrough

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Citigroup restated a “neutral” rating and set a $88.00 target price (up previously from $72.00) on shares of Cooper Companies in a research report on Monday, December 8th. Barclays restated an “overweight” rating and set a $91.00 target price on shares of Cooper Companies in a research report on Monday, December 8th. Robert W. Baird lifted their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Needham & Company LLC reissued a “buy” rating and set a $100.00 price target (up from $94.00) on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 price objective (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $90.15.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.